These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 23163616)

  • 1. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study.
    Kelly CP; Green PH; Murray JA; Dimarino A; Colatrella A; Leffler DA; Alexander T; Arsenescu R; Leon F; Jiang JG; Arterburn LA; Paterson BM; Fedorak RN;
    Aliment Pharmacol Ther; 2013 Jan; 37(2):252-62. PubMed ID: 23163616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge.
    Leffler DA; Kelly CP; Abdallah HZ; Colatrella AM; Harris LA; Leon F; Arterburn LA; Paterson BM; Lan ZH; Murray JA
    Am J Gastroenterol; 2012 Oct; 107(10):1554-62. PubMed ID: 22825365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.
    Leffler DA; Kelly CP; Green PH; Fedorak RN; DiMarino A; Perrow W; Rasmussen H; Wang C; Bercik P; Bachir NM; Murray JA
    Gastroenterology; 2015 Jun; 148(7):1311-9.e6. PubMed ID: 25683116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials.
    Hoilat GJ; Altowairqi AK; Ayas MF; Alhaddab NT; Alnujaidi RA; Alharbi HA; Alyahyawi N; Kamal A; Alhabeeb H; Albazee E; Almustanyir S; Abu-Zaid A
    Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101782. PubMed ID: 34339872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study.
    Lähdeaho ML; Scheinin M; Vuotikka P; Taavela J; Popp A; Laukkarinen J; Koffert J; Koivurova OP; Pesu M; Kivelä L; Lovró Z; Keisala J; Isola J; Parnes JR; Leon F; Mäki M
    Lancet Gastroenterol Hepatol; 2019 Dec; 4(12):948-959. PubMed ID: 31494096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease.
    Leffler D; Schuppan D; Pallav K; Najarian R; Goldsmith JD; Hansen J; Kabbani T; Dennis M; Kelly CP
    Gut; 2013 Jul; 62(7):996-1004. PubMed ID: 22619366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.
    Tye-Din JA; Daveson AJM; Goel G; Goldstein KE; Hand HL; Neff KM; Popp A; Taavela J; Maki M; Isola J; Williams LJ; Truitt KE; Anderson RP;
    Lancet Gastroenterol Hepatol; 2023 May; 8(5):446-457. PubMed ID: 36898393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease.
    Murray JA; Kelly CP; Green PHR; Marcantonio A; Wu TT; Mäki M; Adelman DC;
    Gastroenterology; 2017 Mar; 152(4):787-798.e2. PubMed ID: 27864127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary and symptom assessment in adults with self-reported non-coeliac gluten sensitivity.
    Skodje GI; Minelle IH; Rolfsen KL; Iacovou M; Lundin KEA; Veierød MB; Henriksen C
    Clin Nutr ESPEN; 2019 Jun; 31():88-94. PubMed ID: 31060839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of
    Smecuol E; Constante M; Temprano MP; Costa AF; Moreno ML; Pinto-Sanchez MI; Vázquez H; Stefanolo JP; Gonzalez AF; D'Adamo CR; Niveloni SI; Mauriño E; Verdu EF; Bai JC
    Benef Microbes; 2020 Oct; 11(6):527-534. PubMed ID: 33032471
    [No Abstract]   [Full Text] [Related]  

  • 11. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.
    Lähdeaho ML; Kaukinen K; Laurila K; Vuotikka P; Koivurova OP; Kärjä-Lahdensuu T; Marcantonio A; Adelman DC; Mäki M
    Gastroenterology; 2014 Jun; 146(7):1649-58. PubMed ID: 24583059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity.
    Skodje GI; Sarna VK; Minelle IH; Rolfsen KL; Muir JG; Gibson PR; Veierød MB; Henriksen C; Lundin KEA
    Gastroenterology; 2018 Feb; 154(3):529-539.e2. PubMed ID: 29102613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.
    Schuppan D; Mäki M; Lundin KEA; Isola J; Friesing-Sosnik T; Taavela J; Popp A; Koskenpato J; Langhorst J; Hovde Ø; Lähdeaho ML; Fusco S; Schumann M; Török HP; Kupcinskas J; Zopf Y; Lohse AW; Scheinin M; Kull K; Biedermann L; Byrnes V; Stallmach A; Jahnsen J; Zeitz J; Mohrbacher R; Greinwald R;
    N Engl J Med; 2021 Jul; 385(1):35-45. PubMed ID: 34192430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo.
    Gopalakrishnan S; Durai M; Kitchens K; Tamiz AP; Somerville R; Ginski M; Paterson BM; Murray JA; Verdu EF; Alkan SS; Pandey NB
    Peptides; 2012 May; 35(1):86-94. PubMed ID: 22401908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease.
    Daveson AJM; Tye-Din JA; Goel G; Goldstein KE; Hand HL; Neff KM; Williams LJ; Truitt KE; Anderson RP;
    Aliment Pharmacol Ther; 2020 Jan; 51(2):244-252. PubMed ID: 31769533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celiac disease 2015 update: new therapies.
    Veeraraghavan G; Leffler DA; Kaswala DH; Mukherjee R
    Expert Rev Gastroenterol Hepatol; 2015 Jul; 9(7):913-27. PubMed ID: 25864708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current pharmacological approaches and potential future therapies for Celiac disease.
    Kulkarni A; Patel S; Khanna D; Parmar MS
    Eur J Pharmacol; 2021 Oct; 909():174434. PubMed ID: 34418405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine release after gluten ingestion differentiates coeliac disease from self-reported gluten sensitivity.
    Tye-Din JA; Skodje GI; Sarna VK; Dzuris JL; Russell AK; Goel G; Wang S; Goldstein KE; Williams LJ; Sollid LM; Lundin KE; Anderson RP
    United European Gastroenterol J; 2020 Feb; 8(1):108-118. PubMed ID: 32213060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: a prospective and randomized clinical study.
    Kaukinen K; Peräaho M; Collin P; Partanen J; Woolley N; Kaartinen T; Nuutinen T; Halttunen T; Mäki M; Korponay-Szabo I
    Scand J Gastroenterol; 2005 May; 40(5):564-72. PubMed ID: 16036509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical study: gluten challenge induces symptom recurrence in only a minority of patients who meet clinical criteria for non-coeliac gluten sensitivity.
    Zanini B; Baschè R; Ferraresi A; Ricci C; Lanzarotto F; Marullo M; Villanacci V; Hidalgo A; Lanzini A
    Aliment Pharmacol Ther; 2015 Oct; 42(8):968-76. PubMed ID: 26310131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.